289 related articles for article (PubMed ID: 26720415)
1. Live Cell Analysis and Mathematical Modeling Identify Determinants of Attenuation of Dengue Virus 2'-O-Methylation Mutant.
Schmid B; Rinas M; Ruggieri A; Acosta EG; Bartenschlager M; Reuter A; Fischl W; Harder N; Bergeest JP; Flossdorf M; Rohr K; Höfer T; Bartenschlager R
PLoS Pathog; 2015 Dec; 11(12):e1005345. PubMed ID: 26720415
[TBL] [Abstract][Full Text] [Related]
2. Type I interferon signals in macrophages and dendritic cells control dengue virus infection: implications for a new mouse model to test dengue vaccines.
Züst R; Toh YX; Valdés I; Cerny D; Heinrich J; Hermida L; Marcos E; Guillén G; Kalinke U; Shi PY; Fink K
J Virol; 2014 Jul; 88(13):7276-85. PubMed ID: 24741106
[TBL] [Abstract][Full Text] [Related]
3. Evasion of early innate immune response by 2'-O-methylation of dengue genomic RNA.
Chang DC; Hoang LT; Mohamed Naim AN; Dong H; Schreiber MJ; Hibberd ML; Tan MJA; Shi PY
Virology; 2016 Dec; 499():259-266. PubMed ID: 27716465
[TBL] [Abstract][Full Text] [Related]
4. Dengue Virus Subverts Host Innate Immunity by Targeting Adaptor Protein MAVS.
He Z; Zhu X; Wen W; Yuan J; Hu Y; Chen J; An S; Dong X; Lin C; Yu J; Wu J; Yang Y; Cai J; Li J; Li M
J Virol; 2016 Aug; 90(16):7219-7230. PubMed ID: 27252539
[TBL] [Abstract][Full Text] [Related]
5. How Dengue Virus Circumvents Innate Immunity.
Kao YT; Lai MMC; Yu CY
Front Immunol; 2018; 9():2860. PubMed ID: 30564245
[TBL] [Abstract][Full Text] [Related]
6. Characterization of RyDEN (C19orf66) as an Interferon-Stimulated Cellular Inhibitor against Dengue Virus Replication.
Suzuki Y; Chin WX; Han Q; Ichiyama K; Lee CH; Eyo ZW; Ebina H; Takahashi H; Takahashi C; Tan BH; Hishiki T; Ohba K; Matsuyama T; Koyanagi Y; Tan YJ; Sawasaki T; Chu JJ; Vasudevan SG; Sano K; Yamamoto N
PLoS Pathog; 2016 Jan; 12(1):e1005357. PubMed ID: 26735137
[TBL] [Abstract][Full Text] [Related]
7. STAT2 mediates innate immunity to Dengue virus in the absence of STAT1 via the type I interferon receptor.
Perry ST; Buck MD; Lada SM; Schindler C; Shresta S
PLoS Pathog; 2011 Feb; 7(2):e1001297. PubMed ID: 21379341
[TBL] [Abstract][Full Text] [Related]
8. Antiviral Effects of Clinically-Relevant Interferon-α and Ribavirin Regimens against Dengue Virus in the Hollow Fiber Infection Model (HFIM).
Pires de Mello CP; Drusano GL; Rodriquez JL; Kaushik A; Brown AN
Viruses; 2018 Jun; 10(6):. PubMed ID: 29890736
[TBL] [Abstract][Full Text] [Related]
9. Immune response to dengue virus and prospects for a vaccine.
Murphy BR; Whitehead SS
Annu Rev Immunol; 2011; 29():587-619. PubMed ID: 21219187
[TBL] [Abstract][Full Text] [Related]
10. Dengue virus replication in infected human keratinocytes leads to activation of antiviral innate immune responses.
Surasombatpattana P; Hamel R; Patramool S; Luplertlop N; Thomas F; Desprès P; Briant L; Yssel H; Missé D
Infect Genet Evol; 2011 Oct; 11(7):1664-73. PubMed ID: 21722754
[TBL] [Abstract][Full Text] [Related]
11. Decreased accumulation of subgenomic RNA in human cells infected with vaccine candidate DEN4Δ30 increases viral susceptibility to type I interferon.
Bustos-Arriaga J; Gromowski GD; Tsetsarkin KA; Firestone CY; Castro-Jiménez T; Pletnev AG; Cedillo-Barrón L; Whitehead SS
Vaccine; 2018 Jun; 36(24):3460-3467. PubMed ID: 29752023
[TBL] [Abstract][Full Text] [Related]
12. Rational design of a live attenuated dengue vaccine: 2'-o-methyltransferase mutants are highly attenuated and immunogenic in mice and macaques.
Züst R; Dong H; Li XF; Chang DC; Zhang B; Balakrishnan T; Toh YX; Jiang T; Li SH; Deng YQ; Ellis BR; Ellis EM; Poidinger M; Zolezzi F; Qin CF; Shi PY; Fink K
PLoS Pathog; 2013; 9(8):e1003521. PubMed ID: 23935499
[TBL] [Abstract][Full Text] [Related]
13. Utility of humanized BLT mice for analysis of dengue virus infection and antiviral drug testing.
Frias-Staheli N; Dorner M; Marukian S; Billerbeck E; Labitt RN; Rice CM; Ploss A
J Virol; 2014 Feb; 88(4):2205-18. PubMed ID: 24335303
[TBL] [Abstract][Full Text] [Related]
14. The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens.
Prompetchara E; Ketloy C; Keelapang P; Sittisombut N; Ruxrungtham K
Asian Pac J Allergy Immunol; 2015 Sep; 33(3):182-8. PubMed ID: 26342114
[TBL] [Abstract][Full Text] [Related]
15. Generation and preclinical evaluation of a DENV-1/2 prM+E chimeric live attenuated vaccine candidate with enhanced prM cleavage.
Keelapang P; Nitatpattana N; Suphatrakul A; Punyahathaikul S; Sriburi R; Pulmanausahakul R; Pichyangkul S; Malasit P; Yoksan S; Sittisombut N
Vaccine; 2013 Oct; 31(44):5134-40. PubMed ID: 23973247
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a candidate tetravalent vaccine based on 2'-O-methyltransferase mutants.
Züst R; Li SH; Xie X; Velumani S; Chng M; Toh YX; Zou J; Dong H; Shan C; Pang J; Qin CF; Newell EW; Shi PY; Fink K
PLoS One; 2018; 13(1):e0189262. PubMed ID: 29298302
[TBL] [Abstract][Full Text] [Related]
17. The roles of IRF-3 and IRF-7 in innate antiviral immunity against dengue virus.
Chen HW; King K; Tu J; Sanchez M; Luster AD; Shresta S
J Immunol; 2013 Oct; 191(8):4194-201. PubMed ID: 24043884
[TBL] [Abstract][Full Text] [Related]
18. Dengue vaccine candidates in development.
Durbin AP; Whitehead SS
Curr Top Microbiol Immunol; 2010; 338():129-43. PubMed ID: 19802583
[TBL] [Abstract][Full Text] [Related]
19. Interferon lambda inhibits dengue virus replication in epithelial cells.
Palma-Ocampo HK; Flores-Alonso JC; Vallejo-Ruiz V; Reyes-Leyva J; Flores-Mendoza L; Herrera-Camacho I; Rosas-Murrieta NH; Santos-López G
Virol J; 2015 Sep; 12():150. PubMed ID: 26411318
[TBL] [Abstract][Full Text] [Related]
20. Gamma interferon (IFN-γ) receptor restricts systemic dengue virus replication and prevents paralysis in IFN-α/β receptor-deficient mice.
Prestwood TR; Morar MM; Zellweger RM; Miller R; May MM; Yauch LE; Lada SM; Shresta S
J Virol; 2012 Dec; 86(23):12561-70. PubMed ID: 22973027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
